Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$178.7MCash on Hand
CF+ Cash Runway
Follow RLYB by emailGet an email when RLYB reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about RLYB, unsubscribe in one click. Privacy
📣 What RLYB Says Is Next
late 2026 · “Avenzo plans to present preliminary, updated data from the Phase 1 portion of the AVENTINE-1 study and initial data from the Phase 1 portion of the BEACON-1 study in late 2026.”
Company press release, Jun 1, 2026 · SEC filing
late 2026 · “Avenzo plans to present preliminary, updated data of AVZO-023 in combination with fulvestrant from the Phase 1 portion of the ORION-1 study in late 2026.”
Company press release, Jun 1, 2026 · SEC filing
late 2028 · “The combined company expects its cash balance at closing to fund operations into late 2028 and support advancement of its four clinical-stage programs through multiple clinical milestones, including updated Phase 1 data across the pipeline, initial clinical data for the combination of AVZO-023 and AVZO-021 with fulvestrant, and the initiation of multiple Phase 2 studies across the pipeline.”
Company press release, Jun 1, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Deal Rallybio expects its merger with Avenzo Therapeutics to close after trading on November 20, 2026, and its common stock to list on Nasdaq Capital Market. The $13.90 per share cash distribution will trade with due bills through November 20, 2026, with payment expected November 30, 2026. Form 8-K · SEC filing
Nov 10, 2026 ·
Listing Rallybio will effect a one-for-two reverse stock split effective 12:01 a.m. ET on November 20, 2026, ahead of its merger with Avenzo Therapeutics, reducing outstanding shares from about 5.6 million to about 2.8 million. Post-merger, the company plans to rename itself Avenzo Therapeutics and trade as AVZO on Nasdaq. Form 8-K · SEC filing · Press release
Nov 6, 2026 ·
Listing Rallybio postponed the November 6 closing of its merger with Avenzo Therapeutics because certain conditions tied to listing of the company's shares after closing remain unsatisfied. Form 8-K · SEC filing
Nov 4, 2026 ·
Shareholder vote Stockholders approved the 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan at the November 4, 2026 annual meeting, both effective upon completion of the Avenzo merger. Form 8-K · SEC filing
Oct 27, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 26, 2026 ·
Deal Rallybio's board declared a special cash distribution estimated at $82.7 million, or about $13.56 per share, tied to its merger with Avenzo Therapeutics. Payment is conditioned on stockholder approval at the November 4, 2026 annual meeting, with the merger expected to close around November 6, 2026. Form 8-K · SEC filing
Sep 9, 2026 ·
Leadership Rallybio CFO Jonathan Lieber moves to part-time employment effective September 15, 2026, at a $420,000 base salary with no annual bonus, and remains CFO. His employment ends at closing of the pending Avenzo Therapeutics merger. Form 8-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Feb 2026 · Phase 1 · Results Expected · Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RLYB116 in Healthy Participants Registry primary completion date, not a results date
Jan 2025 · N/A · Results Expected · Study to Assess the Occurrence of HPA-1a Alloimmunization in Women With Higher Risk for Fetal and Neonatal Alloimmune Thrombocytopenia Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
RLYB holds $178.7M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Share count 5,383,937 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full RLYB picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RLYB and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.